The Two-Year Data: STEP 5 Results

STEP 5 was a 104-week (2-year) randomized controlled trial with 304 participants taking semaglutide 2.4 mg weekly versus placebo:

• Average weight loss at 104 weeks: 15.2% of body weight on semaglutide versus 2.6% on placebo .
• Absolute weight loss: Approximately 35 pounds from an average starting weight of 233 pounds.
• Responder rates: 77% of participants lost at least 5% of body weight, 54% lost at least 10%, and 36% lost at least 15%.
• Weight trajectory: Maximum weight loss was achieved around weeks 60 to 68 (approximately 15 months), after which weight stabilized with a very slight upward trend through week 104.

The key takeaway is that semaglutide maintains the vast majority of its weight loss benefit through two full years of treatment, with minimal weight regain during the second year.

Two-Year Timeline

• Months 1 to 4 (titration): Dose escalation from 0.25 mg to 2.4 mg. Weight loss of 5 to 10 pounds. Body adaptation and GI side effects most prominent.
• Months 5 to 10 (peak loss): Fastest weight loss phase. Cumulative loss of 20 to 32 pounds. Metabolic improvements become significant on lab work.
• Months 11 to 15 (maximum weight loss): Weight loss peaks and begins to plateau. Cumulative loss of 30 to 38 pounds. The body establishes a new metabolic equilibrium.
• Months 16 to 20 (stabilization): Weight is relatively stable, with fluctuations of 2 to 4 pounds. The medication prevents the regain that would otherwise occur. Focus shifts entirely to maintenance.
• Months 21 to 24 (sustained maintenance): Weight remains stable within a few pounds of the maximum loss achieved. Health benefits continue to accrue. Total sustained loss of 28 to 38+ pounds.

Health Benefits Sustained at Two Years

The STEP 5 and SELECT trials confirm that semaglutide's health benefits extend well beyond weight:

• Cardiovascular protection: The SELECT trial (median follow-up 40 months) showed a 20% reduction in heart attack, stroke, and cardiovascular death . By 2 years, patients are firmly within the protective window.
• Blood sugar control: A1C improvements seen at 6 to 12 months are sustained through 2 years in patients with prediabetes or type 2 diabetes.
• Blood pressure: Systolic blood pressure reductions of 3 to 6 mmHg persist at 2 years.
• Cholesterol: Triglyceride reductions of 15% to 25% and modest LDL improvements continue.
• Kidney function: The FLOW trial demonstrated a 24% reduction in kidney disease progression with semaglutide .
• Inflammatory markers: CRP and other markers of systemic inflammation remain improved at 2 years.

What Happens in Year Two

The second year on semaglutide is fundamentally different from the first:

• Weight stability, not weight loss: Most patients are no longer actively losing weight. This is normal and expected. The medication is now maintaining your lower weight against your body's natural drive to regain.
• Side effects are minimal: By year two, fewer than 5% of patients report any GI symptoms. The body has fully adapted to the medication.
• Lifestyle habits are established: Two years of healthier eating and activity patterns create lasting behavior changes that support weight maintenance.
• Psychological adjustment: Many patients fully embrace their new body and relationship with food during year two. Some, however, experience body image challenges that benefit from professional support.

Should You Continue Beyond 2 Years?

This is one of the most common questions at the 2-year mark. The evidence strongly favors continuation for most patients:

• The STEP 1 extension data showed that stopping semaglutide led to regain of approximately two-thirds of lost weight within one year .
• The SELECT trial followed patients for up to 5 years, demonstrating ongoing safety and cardiovascular benefit with continued treatment .
• Obesity is a chronic condition. Just as patients continue blood pressure or cholesterol medications long-term, ongoing GLP-1 therapy maintains the metabolic benefits achieved.

Some patients and providers explore dose reduction (for example, from 2.4 mg to 1.7 mg or 1.0 mg) as a maintenance strategy. Results vary, and any change should be gradual and monitored .

Frequently Asked Questions

Do people regain weight in the second year on semaglutide?

A small amount of weight regain (1% to 2% of body weight) is common during the second year as the body fully adapts to its new weight. This is minimal compared to the 10% to 15% total loss and does not indicate medication failure .

Are there long-term risks of taking semaglutide for 2 years?

Clinical trial data through 2 years and real-world experience through 5+ years have not revealed any major new safety concerns. The most important risk factor is gallbladder disease, which is related to the weight loss itself rather than the medication. Regular monitoring remains essential .

Can I switch medications after 2 years on semaglutide?

Yes. If you want to try tirzepatide for additional weight loss or different metabolic benefits, your provider can guide a transition. Some patients alternate between medication classes over time based on their evolving needs.

What labs should I check at the 2-year mark?

Comprehensive panel: A1C, fasting glucose, complete lipid panel, liver enzymes (ALT, AST), kidney function (creatinine, eGFR, UACR), thyroid panel, vitamin B12, vitamin D, iron studies, and CBC. Compare against baseline and 1-year values to track trends.

Is there a maximum recommended duration for semaglutide?

There is no maximum duration specified in the prescribing information. Semaglutide is intended for chronic use, similar to medications for high blood pressure or high cholesterol. Treatment duration should be determined collaboratively with your provider based on your individual health profile.

Plan Your Next Two Years

Two years on semaglutide represents a substantial health transformation. The clinical evidence supports continued treatment for maintaining your results and protecting your cardiovascular and metabolic health. FormBlends provides ongoing clinical support to ensure your treatment remains personalized and effective.

Connect with a licensed provider to review your 2-year results and plan your next phase.